A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Immune checkpoint inhibitors have made significant progress in the treatment of various cancers. However, due to the low ICI responsive rate for the gynecologic cancer, ICI two-drug combination therapy tends to be a predominant way for clinical treatment. Antibody-drug conjugates, a promising therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, An-Jin, Gao, Yang, Shi, Yu-Ying, Dai, Meng-Yuan, Cai, Hong-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813853/
https://www.ncbi.nlm.nih.gov/pubmed/36618922
http://dx.doi.org/10.3389/fphar.2022.1093666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813853/
https://www.ncbi.nlm.nih.gov/pubmed/36618922
http://dx.doi.org/10.3389/fphar.2022.1093666

Ejemplares similares